MX2023010566A - Inhibidores de proteina transportadora vesicular monoaminotransportadora-2 (vmat2) y metodos de uso. - Google Patents

Inhibidores de proteina transportadora vesicular monoaminotransportadora-2 (vmat2) y metodos de uso.

Info

Publication number
MX2023010566A
MX2023010566A MX2023010566A MX2023010566A MX2023010566A MX 2023010566 A MX2023010566 A MX 2023010566A MX 2023010566 A MX2023010566 A MX 2023010566A MX 2023010566 A MX2023010566 A MX 2023010566A MX 2023010566 A MX2023010566 A MX 2023010566A
Authority
MX
Mexico
Prior art keywords
methods
vmat2 inhibitors
vmat2
inhibitors
compositions
Prior art date
Application number
MX2023010566A
Other languages
English (en)
Spanish (es)
Inventor
Nicole Harriott
Nicholas Pagano
Byron A Boon
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MX2023010566A publication Critical patent/MX2023010566A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023010566A 2021-03-22 2022-03-21 Inhibidores de proteina transportadora vesicular monoaminotransportadora-2 (vmat2) y metodos de uso. MX2023010566A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163164135P 2021-03-22 2021-03-22
PCT/US2022/021080 WO2022203984A1 (en) 2021-03-22 2022-03-21 Vmat2 inhibitors and methods of use

Publications (1)

Publication Number Publication Date
MX2023010566A true MX2023010566A (es) 2023-09-21

Family

ID=81325053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010566A MX2023010566A (es) 2021-03-22 2022-03-21 Inhibidores de proteina transportadora vesicular monoaminotransportadora-2 (vmat2) y metodos de uso.

Country Status (33)

Country Link
US (3) US11718618B2 (https=)
EP (2) EP4606429A3 (https=)
JP (1) JP2024511053A (https=)
KR (1) KR20230160308A (https=)
CN (1) CN117062815A (https=)
AR (1) AR125188A1 (https=)
AU (1) AU2022241988A1 (https=)
BR (1) BR112023016273A2 (https=)
CA (1) CA3207452A1 (https=)
CL (1) CL2023002785A1 (https=)
CO (1) CO2023012322A2 (https=)
CR (1) CR20230448A (https=)
DK (1) DK4168409T3 (https=)
DO (1) DOP2023000197A (https=)
EC (1) ECSP23070370A (https=)
ES (1) ES3032498T3 (https=)
FI (1) FI4168409T3 (https=)
HR (1) HRP20250868T1 (https=)
HU (1) HUE072220T2 (https=)
IL (1) IL305054A (https=)
JO (1) JOP20230205A1 (https=)
LT (1) LT4168409T (https=)
MA (1) MA60072B1 (https=)
MD (1) MD4168409T2 (https=)
MX (1) MX2023010566A (https=)
PE (1) PE20240822A1 (https=)
PL (1) PL4168409T3 (https=)
PT (1) PT4168409T (https=)
RS (1) RS67052B1 (https=)
SI (1) SI4168409T1 (https=)
SM (1) SMT202500408T1 (https=)
TW (1) TW202304901A (https=)
WO (1) WO2022203984A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3209005A (en) 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
CA2650904C (en) 2006-05-02 2015-07-07 The Trustees Of The University Of Pennsylvania Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US7897769B2 (en) 2007-10-25 2011-03-01 General Electric Company Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes
US7910738B2 (en) 2007-11-29 2011-03-22 General Electric Company Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US7902364B2 (en) 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US8053578B2 (en) * 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US8013161B1 (en) 2007-12-07 2011-09-06 General Electric Company Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes
US7919622B2 (en) 2007-12-07 2011-04-05 Kande Kankanamalage Dayarathna Amarasinghe Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes
GB2463452A (en) 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
CA2972242A1 (en) 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3351247A1 (en) 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
PT2836241T (pt) 2012-04-10 2019-05-30 Lantheus Medical Imaging Inc Métodos de síntese de radiofármacos
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US8946255B2 (en) 2012-12-28 2015-02-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
JP2016506957A (ja) 2013-01-31 2016-03-07 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. Vmat2のベンゾキノロン阻害剤
US20160031840A1 (en) 2013-03-15 2016-02-04 University Of Kentucky Research Foundation 1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds
GB201313291D0 (en) 2013-07-25 2013-09-11 Ge Healthcare Ltd Imaging neurological disease
WO2015077521A1 (en) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3398602A1 (en) 2014-01-27 2018-11-07 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US9714246B2 (en) 2015-02-06 2017-07-25 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
RS61645B1 (sr) * 2015-10-30 2021-04-29 Neurocrine Biosciences Inc Valbenazin ditozilat i njihovi polimorfi
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ,インコーポレイテッド (S)−(2R,3R,11bR)−3−イソブチル−9,10−ジメトキシ−2,3,4,6,7,11b−ヘキサヒドロ−1H−ピリド[2,1−a]イソキノリン−2−イル2−アミノ−3−メチルブタノエートジ(4−メチルベンゼンスルホネート)の調製のための合成方法
US11999676B2 (en) 2016-04-21 2024-06-04 University Of Kentucky Research Foundation Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
US10668030B2 (en) 2016-04-21 2020-06-02 University Of Kentucky Research Foundation Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
TW201906818A (zh) 2017-05-31 2019-02-16 美商511製藥公司 新穎氘取代之正子發射斷層掃描(pet)顯影劑及其藥理應用
SG11202004165UA (en) 2017-11-08 2020-06-29 Yuhua Li Esters of dihydrotetrabenazine
WO2020086765A1 (en) 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
US12565495B2 (en) 2019-08-12 2026-03-03 Luye Innomind Pharma Shijiazhuang Co., Ltd. VMAT2 inhibitor and preparation method therefor and application thereof
US20210087191A1 (en) 2020-12-04 2021-03-25 Dispersol Technologies, Llc SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS, THEIR SYNTHESIS, AND USE THEREOF
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
TW202322816A (zh) 2021-08-20 2023-06-16 美商紐羅克里生物科學有限公司 篩選 vmat2 抑制劑之方法

Also Published As

Publication number Publication date
BR112023016273A2 (pt) 2023-10-03
PL4168409T3 (pl) 2025-09-01
SMT202500408T1 (it) 2025-11-10
LT4168409T (lt) 2025-06-25
PT4168409T (pt) 2025-06-12
DOP2023000197A (es) 2023-11-15
SI4168409T1 (sl) 2025-08-29
CL2023002785A1 (es) 2024-02-02
CO2023012322A2 (es) 2023-10-09
US11718618B2 (en) 2023-08-08
HRP20250868T1 (hr) 2025-09-26
AU2022241988A1 (en) 2023-10-12
CR20230448A (es) 2023-10-27
ECSP23070370A (es) 2023-10-31
EP4168409B1 (en) 2025-05-07
JOP20230205A1 (ar) 2023-09-04
IL305054A (en) 2023-10-01
MD4168409T2 (ro) 2025-09-30
PE20240822A1 (es) 2024-04-18
CA3207452A1 (en) 2022-09-29
US20250333413A1 (en) 2025-10-30
FI4168409T3 (fi) 2025-06-25
CN117062815A (zh) 2023-11-14
MA60072B1 (fr) 2025-07-31
JP2024511053A (ja) 2024-03-12
EP4606429A3 (en) 2025-12-03
US20240010647A1 (en) 2024-01-11
DK4168409T3 (da) 2025-06-02
WO2022203984A1 (en) 2022-09-29
TW202304901A (zh) 2023-02-01
KR20230160308A (ko) 2023-11-23
ES3032498T3 (en) 2025-07-21
HUE072220T2 (hu) 2025-11-28
EP4168409A1 (en) 2023-04-26
US20230159528A1 (en) 2023-05-25
RS67052B1 (sr) 2025-08-29
AR125188A1 (es) 2023-06-21
EP4606429A2 (en) 2025-08-27

Similar Documents

Publication Publication Date Title
PH12022551503A1 (en) Kras mutant protein inhibitors
CR20230529A (es) Inhibidores de nlrp3
MX2023001917A (es) Inhibidores de la fosfatasa shp2 y metodos para su uso.
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
MX2020009887A (es) Derivados de aminopiridina como inhibidores de ctps1.
ZA202304734B (en) Alpha protein kinase 1 inhibitors and methods of use
MX2024013215A (es) Compuestos para inhibir kif18a
PH12021550400A1 (en) Cardiac sarcomere inhibitors
EA201390317A1 (ru) Усиление действия ингибиторов прорастания картофельных клубней путем применения различных комбинаций агентов
MX2022010944A (es) Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
MX2023011864A (es) Inhibidores de dihidroorotato deshidrogenasa deuterados.
JOP20240157A1 (ar) مشتقات أزا إندول واستخدامها كمثبطات كيناز erk
MX2023002525A (es) Nuevos compuestos.
MX2022002443A (es) Compuestos inhibidores de perk.
EP4706394A3 (en) Use of alkoxypyrazoles as nitrification inhibitors
MX2025008454A (es) Inhibidores de mptp
MX2024005429A (es) Inhibidores de las fosfatidilinositol 3-cinasas-alfa (pi3k-alfa) y metodos para su produccion y uso.
MX2023010910A (es) Nuevos inhibidores macrociclicos de la quinasa de lrrk2.
MX2025014397A (es) Inhibidores de helicasa de adn recq del sindrome de werner (wrn)
ZA202005888B (en) Use of n-functionalized alkoxy pyrazole compounds as nitrification inhibitors
ZA202400821B (en) Inhibitors of transglutaminases
MX2023011004A (es) Compuestos para regular la inmunidad entrenada y métodos para usarlos.
CR20230448A (es) Inhibidores de vmat2 y métodos de uso
MX2023006231A (es) Inhibidores de enzimas.
PH12022552342A1 (en) The rad51 inhibitor compound 67a (2301085-06-1) at a specific dosage for treating cancer